Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.
1. A method for treating abnormal bone in a soft tissue or preventing additional abnormal bone formation in a soft tissue of a subject, the method comprising: administering a therapeutically effective amount of a pharmaceutical composition comprising AZD0530 or AZD0424 to a subject having abnormal bone formation in a soft tissue, thereby treating or preventing additional formation of abnormal bone in a soft tissue of the subject.
2. The method of claim 1 , further comprising a step of detecting the presence of abnormal bone formation in the subject prior to treatment.
3. The method of claim 1 , wherein the subject has been subjected to a musculoskeletal trauma, a spinal cord injury or a central nervous system injury.
4. The method of claim 1 , wherein the formation of abnormal bone is associated with a heterotopic ossification disease.
5. The method of claim 4 , wherein the heterotopic ossification disease is selected from the group consisting of: acquired heterotopic ossification, fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.
6. The method of claim 1 , wherein the therapeutically effective amount of AZD0530 comprises a dose within the range of 5 mg/kg to 250 mg/kg.
7. The method of claim 1 , wherein the therapeutically effective amount of AZD0530 does not cause weight loss greater than 20% of total body mass.
8. The method of claim 1 , wherein the soft tissue comprises muscles, tendons, ligaments and/or fascia.
9. The method of claim 1 , wherein at least one additional agent is administered to the subject.
10. The method of claim 9 , wherein the at least one additional agent comprises a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a lipoxygenase inhibitor, a leukotriene inhibitor, a mast cell stabilizing agent, an anti-histamine, a TNF inhibitor, an IL-23 blocker, or an inhibitor of IL-1 signaling.